NZ630255A - Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof - Google Patents

Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof

Info

Publication number
NZ630255A
NZ630255A NZ630255A NZ63025513A NZ630255A NZ 630255 A NZ630255 A NZ 630255A NZ 630255 A NZ630255 A NZ 630255A NZ 63025513 A NZ63025513 A NZ 63025513A NZ 630255 A NZ630255 A NZ 630255A
Authority
NZ
New Zealand
Prior art keywords
benzo
butoxy
salt
quinolin
thiophen
Prior art date
Application number
NZ630255A
Other languages
English (en)
Inventor
Takuya Minowa
Tetsuya Sato
Yusuke Hoshika
Hidekazu Toyofuku
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49483139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ630255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NZ630255A publication Critical patent/NZ630255A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ630255A 2012-04-23 2013-04-23 Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof NZ630255A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636932P 2012-04-23 2012-04-23
US201361791896P 2013-03-15 2013-03-15
PCT/JP2013/061950 WO2013161830A1 (ja) 2012-04-23 2013-04-23 注射製剤

Publications (1)

Publication Number Publication Date
NZ630255A true NZ630255A (en) 2016-05-27

Family

ID=49483139

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630255A NZ630255A (en) 2012-04-23 2013-04-23 Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof

Country Status (31)

Country Link
US (6) US20150086632A1 (enExample)
EP (1) EP2868318B2 (enExample)
JP (1) JP6249944B2 (enExample)
KR (1) KR102168263B1 (enExample)
CN (4) CN110638752A (enExample)
AR (1) AR090775A1 (enExample)
AU (1) AU2013253518B2 (enExample)
BR (1) BR112014026398B1 (enExample)
CA (1) CA2871398C (enExample)
CO (1) CO7151499A2 (enExample)
CY (1) CY1123195T1 (enExample)
DK (1) DK2868318T4 (enExample)
EA (1) EA026124B1 (enExample)
ES (1) ES2727454T5 (enExample)
HR (1) HRP20190841T4 (enExample)
HU (1) HUE043686T2 (enExample)
IL (1) IL235211A0 (enExample)
IN (1) IN2014DN08870A (enExample)
JO (1) JO3524B1 (enExample)
LT (1) LT2868318T (enExample)
MX (1) MX361722B (enExample)
MY (1) MY169099A (enExample)
NZ (1) NZ630255A (enExample)
PH (1) PH12014502366A1 (enExample)
PL (1) PL2868318T5 (enExample)
PT (1) PT2868318T (enExample)
SG (2) SG10201608684QA (enExample)
SI (1) SI2868318T2 (enExample)
TW (1) TWI641395B (enExample)
UA (1) UA118084C2 (enExample)
WO (1) WO2013161830A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
WO2017106641A1 (en) * 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
EP3411370A1 (en) * 2016-02-01 2018-12-12 Hexal AG Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
EP3500249A1 (en) * 2016-08-16 2019-06-26 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
US11072605B2 (en) * 2017-02-02 2021-07-27 Hexal Ag Crystalline brexpiprazole
EP3946259A1 (en) * 2019-03-28 2022-02-09 Otsuka Pharmaceutical Co., Ltd. Benzoazepine compound-containing freeze-dried composition
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
WO2023036003A1 (zh) 2021-09-07 2023-03-16 四川科伦药物研究院有限公司 注射用布瑞哌唑长效制剂及其制备方法
CN117214053A (zh) * 2023-10-17 2023-12-12 海南卫康制药(潜山)有限公司 一种注射用头孢呋辛钠肌注混悬液的粒度测定方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051281A1 (en) 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
AU2001278779A1 (en) * 2000-08-25 2002-03-04 Senju Pharmaceutical Co. Ltd. Aqueous suspension preparations
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
CN1870980B (zh) * 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20070148100A1 (en) 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
DK2170279T3 (en) 2007-07-31 2018-03-12 Otsuka Pharma Co Ltd PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION
WO2009114521A1 (en) * 2008-03-11 2009-09-17 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
AU2009316708B2 (en) * 2008-11-19 2014-07-17 Boehringer Ingelheim Animal Health USA Inc. Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
RU2535089C2 (ru) 2010-08-24 2014-12-10 Оцука Фармасьютикал Ко., Лтд. Суспензия и затвердевшая композиция, содержащие производное карбостирила и силиконовое масло и/или производное силиконового масла
CA2814840C (en) * 2010-10-18 2018-08-28 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
RS65237B1 (sr) * 2011-03-18 2024-03-29 Alkermes Pharma Ireland Ltd Farmaceutske kompozicije koje sadrže sorbitan estre
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
ES2950418T3 (es) * 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Also Published As

Publication number Publication date
UA118084C2 (uk) 2018-11-26
CN107536802A (zh) 2018-01-05
EP2868318A4 (en) 2015-12-09
PL2868318T5 (pl) 2022-06-20
CN104363912A (zh) 2015-02-18
KR102168263B1 (ko) 2020-10-21
EP2868318B1 (en) 2019-03-06
EP2868318A1 (en) 2015-05-06
ES2727454T5 (es) 2022-05-13
JP6249944B2 (ja) 2017-12-20
IN2014DN08870A (enExample) 2015-05-22
US20200163960A1 (en) 2020-05-28
EP2868318B2 (en) 2022-01-26
SG11201406775UA (en) 2014-12-30
JO3524B1 (ar) 2020-07-05
PL2868318T3 (pl) 2019-09-30
MX361722B (es) 2018-12-14
EA026124B1 (ru) 2017-03-31
TW201406401A (zh) 2014-02-16
BR112014026398A2 (pt) 2017-06-27
SI2868318T2 (sl) 2022-04-29
MY169099A (en) 2019-02-18
HRP20190841T1 (hr) 2019-07-26
TWI641395B (zh) 2018-11-21
DK2868318T3 (da) 2019-06-03
CN111888329A (zh) 2020-11-06
MX2014012734A (es) 2015-04-10
US20250241909A1 (en) 2025-07-31
HRP20190841T4 (hr) 2022-03-04
AR090775A1 (es) 2014-12-03
WO2013161830A1 (ja) 2013-10-31
HK1205678A1 (en) 2015-12-24
CA2871398A1 (en) 2013-10-31
PH12014502366B1 (en) 2015-01-12
US20240277702A1 (en) 2024-08-22
HUE043686T2 (hu) 2019-09-30
IL235211A0 (en) 2014-12-31
AU2013253518A1 (en) 2014-11-06
LT2868318T (lt) 2019-07-25
BR112014026398B1 (pt) 2022-11-29
US20150086632A1 (en) 2015-03-26
US10624889B2 (en) 2020-04-21
US20180092910A1 (en) 2018-04-05
EA201491937A1 (ru) 2015-03-31
US20220305007A1 (en) 2022-09-29
ES2727454T3 (es) 2019-10-16
KR20150003336A (ko) 2015-01-08
PT2868318T (pt) 2019-06-07
PH12014502366A1 (en) 2015-01-12
CA2871398C (en) 2021-04-27
CY1123195T1 (el) 2021-10-29
AU2013253518B2 (en) 2017-10-05
SG10201608684QA (en) 2016-12-29
CO7151499A2 (es) 2014-12-29
JPWO2013161830A1 (ja) 2015-12-24
CN110638752A (zh) 2020-01-03
SI2868318T1 (sl) 2019-06-28
DK2868318T4 (da) 2022-03-28

Similar Documents

Publication Publication Date Title
NZ630255A (en) Injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
ZA201402333B (en) Tablet including 7-[4-(4-benzo[b]thiophen-4-yl-piperazin -1-yl)butoxy]-1h-quinolin-2-one or salt thereof
PH12015500925B1 (en) Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
CA2865011C (en) Methods and compositions for treating huntington's disease
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX348823B (es) Formulaciones estables de linaclotida.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX349802B (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
GB201106750D0 (en) Novel compounds
MA44637B1 (fr) Composes hétérocycliques et leurs utilisations
PH12015501096A1 (en) Composition for immediate and extended release
PL2588086T3 (pl) Kompozycje farmaceutyczne zawierające monohydrat mleczanu 4-amino-5-fluoro-3-[6-(4-metylopiperazyn-1-ylo)-1H-benzimidazol-2-ilo]-1H-chinolin-2-onu
ZA201509016B (en) Compositions, methods & systems for respiratory delivery of three or more active agents
NZ748572A (en) Pharmaceutical compositions having improved storage stability
EP2888373A4 (en) ANTIBODY AGAINST ARIPIPRAZOLE AND USE THEREOF
PL402710A1 (pl) Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania
SG182629A1 (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
UA111434C2 (uk) Фармацевтична композиція, що містить фімасартан і гідрохлортіазид
PL2841549T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PL2841548T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
IL230484A (en) "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MD4411B1 (ro) Preparat medicamentos ce include clorură de benzildimetil(3-[miristoilamino]-propil)-amoniu şi aplicarea acestuia pentru tratamentul şi profilaxia bolilor infecţioase şi a afecţiunilor inflamatoare purulente de diverse etiologii şi localizări

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2018 BY CPA GLOBAL

Effective date: 20170324

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2019 BY CPA GLOBAL

Effective date: 20180309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2020 BY CPA GLOBAL

Effective date: 20190307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2021 BY CPA GLOBAL

Effective date: 20200312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2022 BY CPA GLOBAL

Effective date: 20210312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2023 BY CPA GLOBAL

Effective date: 20220310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2024 BY CPA GLOBAL

Effective date: 20230309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250307